Stock Analysts’ updated eps estimates for Monday, August 14th:

Apple (NASDAQ:AAPL) was given a $175.00 price target by analysts at Sanford C. Bernstein. The firm currently has a buy rating on the stock.

TASER International (NASDAQ:AAXN) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Axon Enterprise, Inc. engages in the development, manufacture and sale of conducted electrical weapons for the law enforcement, federal, military, corrections, private security and personal defense markets. Its operating segment consists of TASER Weapons and Axon segments. TASER Weapons segment involves in the sale of conducted electrical weapons, accessories and other products and services. Axon segment focuses on devices, wearables, applications, cloud and mobile products. Axon Enterprise Inc., formerly known as TASER International Inc., is headquartered in Scottsdale, AZ. “

Ahold NV (OTCMKTS:ADRNY) was upgraded by analysts at Zacks Investment Research from a hold rating to a strong-buy rating. The firm currently has $23.00 target price on the stock. According to Zacks, “Koninklijke Ahold Delhaize N.V. provides retail stores which offer food and non-food products primarily in the United States and Europe. The Company operates supermarkets, convenience stores, compact hypers, pick-up points and gasoline stations as well as specialty stores. Koninklijke Ahold Delhaize N.V., formerly known as Ahold N.V., is based in Zaandam, Netherlands. “

Alarm.com Holdings (NASDAQ:ALRM) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. They currently have $46.00 target price on the stock. According to Zacks, “Alarm.com Holdings, Inc. offers interactive security solutions for home and business owners. The Company offers security systems which include image sensor, crash and smash protection, web control, mobile access and video monitoring. Alarm.com Holdings, Inc. is based in VIENNA, United States. “

Arista Networks (NYSE:ANET) had its outperform rating reiterated by analysts at William Blair.

Amira Nature Foods (NYSE:ANFI) was upgraded by analysts at Zacks Investment Research from a strong sell rating to a hold rating. According to Zacks, “Amira Nature Foods Ltd. provides packaged Indian specialty rice. The Company sells Basmati rice, premium long-grain rice under their flagship Amira brand as well as under other third party brands. It participates across the entire rice supply chain from the procurement of paddy to its storage, aging, processing into rice, packaging, distribution and marketing. Amira Nature Foods Ltd. is headquartered in Dubai, United Arab Emirates. “

Aqua Metals (NASDAQ:AQMS) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Aqua Metals, Inc. is involved in the business of recycling lead through a process called AquaRefining(TM). Its AquaRefining process elements consists of non-toxic solvent that dissolves lead compounds and an electro-chemical process and electrolyze that converts the dissolved lead compounds into pure, primary grade lead. The Company’s AquaRefining process generates outputs consists of primary lead ingots; lead acid batteries grade lead alloy ingots; cleaned plastic chips, recovered from battery casings and sulphuric acid. Aqua Metals, Inc. is based in Oakland, California. “

Algonquin Power & Utilities Corp. (NYSE:AQN) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. They currently have $12.00 price target on the stock. According to Zacks, “Algonquin Power & Utilities Corp. is a renewable energy and regulated utility company engaged in the ownership of power generation facilities, and water and energy utilities primarily in North America. The Corporation invests in hydroelectric, wind and solar power facilities, and sustainable utility distribution businesses (water, electricity and natural gas) through its subsidiaries. Algonquin Power & Utilities Corp. is headquartered in Oakville, Canada. “

Argos Therapeutics (NASDAQ:ARGS) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Argos Therapeutics is a biopharmaceutical company which focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on its Arcelis (TM) technology platform. Argos Therapeutics is based in Durham, United States. “

Assembly Biosciences (NASDAQ:ASMB) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Assembly Biosciences, Inc. is a biopharmaceutical company. It develops therapies for infectious diseases and other disorders of the gastrointestinal (GI) system. Assembly’s product portfolio consists of two late stage assets: VEN 307 for relief from pain associated with anal fissures and VEN 308 for the treatment of fecal incontinence. The Company is also developing novel microbiome-based technology for targeted oral delivery of therapeutic bacteria, complex proteins, viral antigens and small molecules to treat intractable infectious diseases of the GI tract, such as C. difficile infections. Assembly Biosciences Inc., formerly known as Ventrus Biosciences, Inc., is based in New York. “

Asure Software (NASDAQ:ASUR) had its buy rating reaffirmed by analysts at Canaccord Genuity. The firm currently has a $18.00 target price on the stock.

Athersys (NASDAQ:ATHX) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. Zacks Investment Research currently has $1.75 target price on the stock. According to Zacks, “Athersys is a biopharmaceutical company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The company’s lead product candidate, ATHX-105, is an oral, selective 5HT2c receptor agonist in Phase I clinical trials for the treatment of obesity. The company is also developing other orally active pharmaceutical product candidates for the treatment of metabolic and central nervous system disorders, utilizing proprietary technologies, including Random Activation of Gene Expression (RAGE). Athersys is developing MultiStem(r), its patented, adult-derived “off the shelf” stem cell product platform, for multiple disease indications, including damage caused by myocardial infarction, bone marrow transplantation/oncology support, ischemic stroke and other indications. “

Aircastle Limited (NYSE:AYR) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “AIRCASTLE LTD are a global company that acquires and leases high utility commercial jet aircraft to passenger and cargo airlines throughout the world. High utility aircraft are generally modern, operationally efficient jets with a large operator base and long useful lives. They also make investments in other aviation assets, including debt securities secured by commercial jet aircraft. “

Bill Barrett Corporation (NYSE:BBG) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Bill Barrett Corporation, headquartered in Denver, explores for and develops oil and natural gas in the Rocky Mountain region of the United States. The Company has projects in nine basins in the Rocky Mountains. “

Becton, Dickinson and (NYSE:BDX) had its buy rating reiterated by analysts at Cowen and Company. The firm currently has a $230.00 target price on the stock.

Burlington Stores (NYSE:BURL) had its buy rating reaffirmed by analysts at Cowen and Company. The firm currently has a $105.00 price target on the stock.

Canadian Solar (NASDAQ:CSIQ) had its hold rating reiterated by analysts at Cowen and Company. The firm currently has a $16.00 target price on the stock.

CenturyLink (NYSE:CTL) had its neutral rating reissued by analysts at Cowen and Company.

Delta Air Lines (NYSE:DAL) had its buy rating reaffirmed by analysts at Cowen and Company. The firm currently has a $66.00 price target on the stock.

Amicus Therapeutics (NASDAQ:FOLD) had its buy rating reaffirmed by analysts at Cowen and Company. They currently have a $16.00 price target on the stock.

Global Blood Therapeutics (NASDAQ:GBT) had its outperform rating reiterated by analysts at Cowen and Company. Cowen and Company currently has a $83.00 target price on the stock.

Iconix Brand Group (NASDAQ:ICON) had its hold rating reiterated by analysts at Cowen and Company. They currently have a $9.00 target price on the stock.

Myriad Genetics (NASDAQ:MYGN) had its hold rating reiterated by analysts at Cowen and Company. Cowen and Company currently has a $25.00 target price on the stock.

NVIDIA Corporation (NASDAQ:NVDA) had its buy rating reaffirmed by analysts at Argus. Argus currently has a $175.00 target price on the stock.

Pfizer (NYSE:PFE) had its buy rating reaffirmed by analysts at Cowen and Company. Cowen and Company currently has a $43.00 target price on the stock.

Qiagen N.V. (NASDAQ:QGEN) had its hold rating reissued by analysts at Cowen and Company. Cowen and Company currently has a $33.00 price target on the stock.

Roche Holding (NASDAQ:RHHBY) had its buy rating reiterated by analysts at Cowen and Company. They currently have a $38.00 price target on the stock.

Skechers U.S.A. (NYSE:SKX) had its buy rating reaffirmed by analysts at Cowen and Company. Cowen and Company currently has a $35.00 target price on the stock.

Snap (NYSE:SNAP) had its neutral rating reiterated by analysts at Cantor Fitzgerald. The firm currently has a $15.00 target price on the stock, down from their previous target price of $17.00.

Sysco Corporation (NYSE:SYY) had its buy rating reiterated by analysts at Wells Fargo & Company. The analysts wrote, “We believe the exit of low-margin chain & national customers is the primary driver, as these customers have now declined for three straight quarters. We anticipate declines for national accounts to last into Q1, with y/y compares easing in Q2 of FY18 plus new business wins to drive reaccelerating case growth ahead. For FY18, we model +3.7% total sales growth comprised of +1.6% Broadline cases, +1.3% of inflation and local customer share gains (of 2%).””

Thin Film Electronics ASA (NASDAQ:TFECY) had its buy rating reissued by analysts at Cowen and Company. The firm currently has a $8.00 price target on the stock.

Communications Sales & Leasing,Inc. (NASDAQ:UNIT) had its overweight rating reissued by analysts at J P Morgan Chase & Co. The firm currently has a $31.00 target price on the stock.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.